These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10593704)

  • 1. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-dose combination formulations for tuberculosis treatment.
    Sbarbaro J; Blomberg B; Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
    [No Abstract]   [Full Text] [Related]  

  • 3. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.
    Tuber Lung Dis; 1994 Jun; 75(3):180-1. PubMed ID: 7919308
    [No Abstract]   [Full Text] [Related]  

  • 4. Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings?
    Singh S
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):880-2. PubMed ID: 11573905
    [No Abstract]   [Full Text] [Related]  

  • 5. Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.
    Fourie PB; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S368-70; discussion S381-7. PubMed ID: 10593720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance of fixed-dose combinations of anti-tuberculosis medications. Proceedings of an IUATLD/WHO workshop, 29th IUATLD World Conference. Bangkok, Thailand, November 1998.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S281-387. PubMed ID: 10636712
    [No Abstract]   [Full Text] [Related]  

  • 7. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.
    Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.
    Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S362-7; discussion S381-7. PubMed ID: 10593719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for anti-tuberculosis drug tender requests.
    Trébucq A; Caudron JM; Pinel J
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S358-61; discussion S381-7. PubMed ID: 10593718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
    McIlleron H; Wash P; Burger A; Folb P; Smith P
    Int J Tuberc Lung Dis; 2002 Apr; 6(4):356-61. PubMed ID: 11936746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
    Blomberg B; Spinaci S; Fourie B; Laing R
    Bull World Health Organ; 2001; 79(1):61-8. PubMed ID: 11217670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?
    Blomberg B; Kitler ME; Milstien J; Dellepiane N; Fanning A; Norval PY; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S371-80; discussion S381-7. PubMed ID: 10593721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.